This is a long hold. The growth prospects aren't exciting enough to expect a surge in share price anytime soon. I believe it's undervalued at these prices and will remain fully subscribed to the DRP for the foreseeable future.
There's a lot riding on the US business succeeding and Australian companies don't always do well overseas. The Australian business provides adequate stability to mitigate this risk, though the squeezing of the local retail margins poses their own risk.
- Forums
- ASX - By Stock
- 2016 Guidance Affirmed
This is a long hold. The growth prospects aren't exciting enough...
-
- There are more pages in this discussion • 253 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add EPW (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
ACW
ACTINOGEN MEDICAL LIMITED
Andy Udell, CCO
Andy Udell
CCO
SPONSORED BY The Market Online